Table 3.

Treatment outcomes of pembrolizumab.

	High PD-L1 (n = 9)	Low PD-L1 (n = 17)	Total (n = 26)	P-value
Cycles				0.016
Median (range)	7 (3–20)	5 (3–9)	6 (3–20)
Best response
CR	0 (0%)	0 (0%)	0 (0%)
PR	5 (56%)	1 (6%)	6 (23%)
SD	2 (22%)	5 (29%)	7 (27%)
PD	2 (22%)	11 (65%)	13 (50%)
Tumor response rate
Overall response (ORR, %)*	5 (56%)	1 (6%)	6 (23%)	0.004
Disease control (DCR, %)†	7 (78%)	6 (35%)	13 (50%)	0.019

PD-L1, programmed cell death ligand 1; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate; DCR, diseased control rate.

*ORR = (CR + PR)/(CR + PR + SD + PD)*100 (%).

^†DCR = (CR + PR + SD)/(CR + PR + SD + PD)*100 (%).